RCS - Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS

FTI Consulting

22/09/2025 09:51

RNS Number : 2469A

Redx Pharma Limited

22 September 2025

 

 

 

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx to present new data for zelasudil (RXC007) for the treatment of Idiopathic Pulmonary Fibrosis at ERS

The oral presentation "Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)" will be presented on Sunday 28 September

Alderley Park, UK,  22 September  2025 Redx Pharma, the clinical-stage biotechnology company focused on developing novel, small molecule, targeted therapeutics for fibrotic disease, will present new data from the zelasudil Phase 2a signal searching study in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) meeting in Amsterdam. The oral presentation will be given by Professor Toby Maher, zelasudil Phase 2 Chief Investigator and Professor of Clinical Medicine and Director of the Interstitial Lung Disease Programme at Keck School of Medicine at the University of Southern California.

Zelasudil is a potent, oral, small molecule, selective, Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor. The Phase 2a study assessed safety, tolerability, pharmacokinetic and initial efficacy in patients with IPF.

IPF is a debilitating disease of the lungs which progressively causes scarring and a reduction in lung function. Occurring primarily in older adults (>50 years old), it involves irreversible and variable scarring, stiffening, and thickening of the lung tissues, leading to patients experiencing shortness of breath and lack of oxygen absorption. Over 170,000 patients suffer with IPF[i] and around a further 53,000 people are diagnosed each year (US, 5 EU, Japan). Patients diagnosed with IPF have an estimated life expectancy of 3 to 5 years[ii]. There is no known cure and current treatment only slows progression of the disease.

 

Oral Presentation Details:
Title:Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)
Session:Emerging Clinical Trials in Pulmonary Fibrosis
Day/Date:Sunday 28 September 2025
Presentation Time:11:05-11:15 CEST
Location:RAI Amsterdam, Europaboulevard, 1079 MW Amsterdam, Netherlands from 27 September to 1 October, 2025


 

For further information, please contact:
Redx Pharma Limited
Cailtin Pearson, Head of Communications
info@redxpharma.com
T: +44 (0)1625 469 918
FTI Consulting
T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin


 

About Redx Pharma Limited

Redx Pharma is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicine for the treatment of fibrotic disease. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry-leading ROCK inhibitor portfolio through the clinic, comprising of zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, and RXC008, a GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry, translational science and clinical development, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which include the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor, now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

[i] Patient numbers (diagnosed prevalence) & market size forecast data sourced from Global Data (US, EU5, Japan)

 

[ii] Clinical Estimates from Hyun 2015, Ley 2012, Raghu 2006

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRADZGZLRZLGKZG